-+ 0.00%
-+ 0.00%
-+ 0.00%

NewcelX publishes updated corporate presentation

PUBT·04/20/2026 11:37:52
Listen to the news
NewcelX publishes updated corporate presentation
  • NewcelX published updated corporate presentation highlighting Type 1 Diabetes flagship program NCEL-101.
  • Presentation includes strategic collaboration with Eledon integrating NewcelX stem-cell-derived islet replacement platform with Eledon anti-CD40L monoclonal antibody tegoprubart.
  • Update frames combined approach as strategy to support durable graft survival for Type 1 Diabetes.
  • Management plans to present updated materials at Swiss Biotech Conference.
  • Release posted at https://www.newcelx.com.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NLS Pharmaceutics Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604200737PRIMZONEFULLFEED9692954) on April 20, 2026, and is solely responsible for the information contained therein.